IMNM - Immunome to buy AL102 a phase 3 asset for treatment of desmoid tumors February, 06 2024 08:14 AM Immunome Inc. 2024-02-06 08:14:45 ET More on Advaxis, Immunome, etc. Immunome: Why It Has Doubled Over The Last Month Immunome a new outperform at Wedbush on cancer platforms Historical earnings data for Advaxis Financial information for Advaxis Seeking Alpha’s Quant Rating on Immunome For further details see: Immunome to buy AL102, a phase 3 asset for treatment of desmoid tumors